Human papillomavirus vaccine: Now for boys too?

Current Opinion in Pediatrics

Volumn 23, Issue 1, 2011, Pages 78-84

  Jenson, Hal B ^a,b   Baltimore, Robert S ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervarix; cervical cancer; Gardasil; genital warts; HPV2; HPV4; human papillomavirus; penile perineal perianal cancer; vaccination; vaginal cancer; vulvar cancer

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENITAL TRACT CANCER; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 4; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE REACTION; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEROCONVERSION; SYNCOPE; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; CHILD; GAMMAPAPILLOMAVIRUS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MEN'S HEALTH; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 78751606932     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3283426580     Document Type: Review

References (27)

1. Jenson HB. Human papillomavirus vaccine: a paradigm shift for pediatricians. Curr Opin Pediatr 2009; 21:112-121.
2. Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56:1-24.
3. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of human papillomavirus infection: provisional recommendations for immunization of girls and women with quadrivalent human papillomavirus vaccine. Pediatrics 2007 120 666-668
4. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010; 59:630-632.
5. Block SL, Nolan T, Sattler C, et al. for the Protocol 016 Study Group: Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-2145.
6. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:201-209.
7. Food and Drug Administration. Product approval-prescribing information [package insert]. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck & Co., Inc. Food and Drug Administration; 2009. http://www.fda.gov/biologicsbloodvaccines/ vaccines/approvedproducts/ucm094042.htm. [Accessed 1 November 2010]
8. Slade BA, Leidel L, Vellozzi C, et al. Post licensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302:750-757.
9. Centers for Disease Control and Prevention. Syncope after vaccination - United States, January 2005-July 2007. MMWR 2008; 57:457-460.
10. World Health Organization. HPV IARC monograph summary. Lancet Oncol 2005; 6:204.
11. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030-3044.
12. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10:1915-1923.
13. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337:a769.
14. Elbasha ED, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination in the United Kingdom. Emerg Infect Dis 2007; 13:28-41.
15. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339:b3884.
16. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85:499-502.
17. Garland SM. Prevention strategies against human papillomavirus in males. Gynecol Oncol 2010; 117:S20-S25.
18. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years: United States, 2009. MMWR 2010; 59:1018-1023.
19. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theoryinformed, systematic review. Prev Med 2007; 45:107-114.
20. Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health 2009; 45:453-462.
21. Gerend MA, Weibley E, Bland H. Parental response to human papillomavirus vaccine availability: uptake and intentions. J Adolesc Health 2009; 45:528-531.
22. Daley MF, Crane LA, Markowitz LE, et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics 2010; 126:425-433.
23. Torrko KC, Gershman K, Crane LA, et al. Testing for Chlamydia and sexual history taking in adolescent females: results from a statewide survey of Colorado primary care providers. Pediatrics 2000; 106:E32.
24. Wimberly YH, Hogben M, Moore-Ruffin J, et al. Sexual history-taking among primary care physicians. J Natl Med Assoc 2006; 98:1924-1929.
25. Liddon N, Hood J, Wynn BA, Markowitz LE. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health 2010; 46:113-123.
26. Reiter PL, McRee AL, Gottlieb SL, Brewer NT. HPV vaccine for adolescent males: acceptability to parents postvaccine licensure. Vaccine 2010; 28:6292-6297.
27. Weiss TW, Zimet GD, Rosenthal SL, et al. Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females. J Adolesc Health 2010; 47:3-11.